ArticleAmerican journal of public health2018
Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011-2015: A Capture-Recapture Analysis.
Open access · greenAbstract read
In one paragraph
Article in American journal of public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 3 pooled it
14.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 3 syntheses or guidelines pooled it, 162 citations in OpenAlex.
- Evidence-based framework for identifying opioid use disorder in administrative data: A systematic review and methodological development study.Pain medicine (Malden, Mass.) · 2026Pooled it
- Predictive Models for Identifying Adult Patients at High Risk of Developing Opioid-Related Harms: a Systematic Review.Drug safety · 2025Pooled it
- A Systematic Review of Simulation Models to Track and Address the Opioid Crisis.Epidemiologic reviews · 2022Pooled it
- Mindfulness-Oriented Recovery Enhancement vs Supportive Group Therapy for Co-occurring Opioid Misuse and Chronic Pain in Primary Care: A Randomized Clinical Trial.JAMA internal medicine · 2022Trial
- A population-based study exploring racial and gender inequities in polysubstance-related deaths across the United States from 2004 to 2022.Addiction (Abingdon, England) · 2026Article
- Projected Outcomes of Reducing Federal Funding for Syringe Service Programs via Executive Order.JAMA network open · 2026Article
- Impacts of personal or family COVID-19 infection on health-related quality of life among patients with opioid use disorder.Journal of substance use · 2026Article
- Estimating community-level prevalence of opioid use disorder: Extrapolating from Medicaid claims data and other publicly available data sources in Ohio, USA.Addiction (Abingdon, England) · 2026Article
- Prevalence of Substance Use Disorders Across Five Community Health Centers in Boston, Massachusetts.Journal of general internal medicine · 2026Article
- Barriers and facilitators to implementing status-neutral HIV care in an urban jail system.Health & justice · 2026Article
- Productivity Losses From Substance Use Disorder in the U.S. in 2023.American journal of preventive medicine · 2026Article
- Incarceration history and HIV testing among people who inject drugs in the Boston metro area: a pooled cross-sectional study.BMC public health · 2026Article
- Article
- Medications for Opioid Use Disorder in County Jails - Outcomes after Release.The New England journal of medicine · 2025Observational
- Differences and similarities between the genetic architecture of lifetime substance use across different substances.Psychological medicine · 2025Article
- Global, regional, and national burden of opioid use disorder from 1990 to 2021: a statistical analysis of incidence, mortality, and disability-adjusted life years.BMC public health · 2025Article
- Prevalence of adults with stimulant misuse and/or stimulant use disorder in Massachusetts, USA, 2014-2021.Addiction (Abingdon, England) · 2025Article
- Comparison of heroin and fentanyl use in US nationally representative surveys.Addiction science & clinical practice · 2025Article
- Improving racial/ethnic health equity and naloxone access among people at risk for opioid overdose: A simulation modeling analysis of community-based naloxone distribution strategies in Massachusetts, United States.Addiction (Abingdon, England) · 2025Article
- Opioid use disorder prevalence in 57 New York counties from 2017 to 2019: A Bayesian evidence synthesis.Drug and alcohol dependence · 2025Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Joshua A BarocasJoshua A. Barocas, Jianing Wang, Jake R. Morgan, and Benjamin P. Linas are with the Division of Infectious Diseases, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA. Laura F. White is with the Department of Biostatistics, Boston University School of Public Health. Alexander Y. Walley, Marc R. LaRochelle, and Jeffrey H. Samet are with the Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center. Dana Bernson is with the Massachusetts Department of Public Health, Boston. Thomas Land is with the University of Massachusetts Medical School, Boston.
Laura F WhiteJoshua A. Barocas, Jianing Wang, Jake R. Morgan, and Benjamin P. Linas are with the Division of Infectious Diseases, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA. Laura F. White is with the Department of Biostatistics, Boston University School of Public Health. Alexander Y. Walley, Marc R. LaRochelle, and Jeffrey H. Samet are with the Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center. Dana Bernson is with the Massachusetts Department of Public Health, Boston. Thomas Land is with the University of Massachusetts Medical School, Boston.
Jianing WangJoshua A. Barocas, Jianing Wang, Jake R. Morgan, and Benjamin P. Linas are with the Division of Infectious Diseases, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA. Laura F. White is with the Department of Biostatistics, Boston University School of Public Health. Alexander Y. Walley, Marc R. LaRochelle, and Jeffrey H. Samet are with the Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center. Dana Bernson is with the Massachusetts Department of Public Health, Boston. Thomas Land is with the University of Massachusetts Medical School, Boston.
Alexander Y WalleyJoshua A. Barocas, Jianing Wang, Jake R. Morgan, and Benjamin P. Linas are with the Division of Infectious Diseases, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA. Laura F. White is with the Department of Biostatistics, Boston University School of Public Health. Alexander Y. Walley, Marc R. LaRochelle, and Jeffrey H. Samet are with the Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center. Dana Bernson is with the Massachusetts Department of Public Health, Boston. Thomas Land is with the University of Massachusetts Medical School, Boston.
Marc R LaRochelleJoshua A. Barocas, Jianing Wang, Jake R. Morgan, and Benjamin P. Linas are with the Division of Infectious Diseases, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA. Laura F. White is with the Department of Biostatistics, Boston University School of Public Health. Alexander Y. Walley, Marc R. LaRochelle, and Jeffrey H. Samet are with the Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center. Dana Bernson is with the Massachusetts Department of Public Health, Boston. Thomas Land is with the University of Massachusetts Medical School, Boston.
Dana BernsonJoshua A. Barocas, Jianing Wang, Jake R. Morgan, and Benjamin P. Linas are with the Division of Infectious Diseases, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA. Laura F. White is with the Department of Biostatistics, Boston University School of Public Health. Alexander Y. Walley, Marc R. LaRochelle, and Jeffrey H. Samet are with the Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center. Dana Bernson is with the Massachusetts Department of Public Health, Boston. Thomas Land is with the University of Massachusetts Medical School, Boston.
Thomas LandJoshua A. Barocas, Jianing Wang, Jake R. Morgan, and Benjamin P. Linas are with the Division of Infectious Diseases, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA. Laura F. White is with the Department of Biostatistics, Boston University School of Public Health. Alexander Y. Walley, Marc R. LaRochelle, and Jeffrey H. Samet are with the Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center. Dana Bernson is with the Massachusetts Department of Public Health, Boston. Thomas Land is with the University of Massachusetts Medical School, Boston.
Jake R MorganJoshua A. Barocas, Jianing Wang, Jake R. Morgan, and Benjamin P. Linas are with the Division of Infectious Diseases, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA. Laura F. White is with the Department of Biostatistics, Boston University School of Public Health. Alexander Y. Walley, Marc R. LaRochelle, and Jeffrey H. Samet are with the Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center. Dana Bernson is with the Massachusetts Department of Public Health, Boston. Thomas Land is with the University of Massachusetts Medical School, Boston.
Jeffrey H SametJoshua A. Barocas, Jianing Wang, Jake R. Morgan, and Benjamin P. Linas are with the Division of Infectious Diseases, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA. Laura F. White is with the Department of Biostatistics, Boston University School of Public Health. Alexander Y. Walley, Marc R. LaRochelle, and Jeffrey H. Samet are with the Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center. Dana Bernson is with the Massachusetts Department of Public Health, Boston. Thomas Land is with the University of Massachusetts Medical School, Boston.
Benjamin P LinasJoshua A. Barocas, Jianing Wang, Jake R. Morgan, and Benjamin P. Linas are with the Division of Infectious Diseases, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA. Laura F. White is with the Department of Biostatistics, Boston University School of Public Health. Alexander Y. Walley, Marc R. LaRochelle, and Jeffrey H. Samet are with the Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center. Dana Bernson is with the Massachusetts Department of Public Health, Boston. Thomas Land is with the University of Massachusetts Medical School, Boston.
Boston Medical Center · US
Funding
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI JOSEPH W HOGAN · 1998 to 2026
$51.7MUtilization of health services after engagement with opioid use disorder (OUD) treatment provider by individuals with and without post-traumatic stress disorderP30DA040500 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Bruce R Schackman · 2015 to 2026
$20.7MClinical Addiction Research and Education ProgramR25DA013582 · NIDA · BOSTON MEDICAL CENTER · PI JEFFREY H. SAMET, Alexander Yale Walley · 2001 to 2026
$8.9MResearching Effective Strategies to Prevent Opioid Death (RESPOND)R01DA046527 · NIDA · BOSTON MEDICAL CENTER · PI Benjamin P. Linas · 2018 to 2026
$7.2MBU Clinical HIV/AIDS Research Training Program (BU-CHART)T32AI052074 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Benjamin P. Linas · 2003 to 2026
$6.7MThe Lifespan/Brown Criminal Justice Research Program on Substance Use and HIVR25DA037190 · NIDA · MIRIAM HOSPITAL · PI CURT G BECKWITH · 2014 to 2026
$3.5MSimulation Modeling to Improve HIV/HCV Screening, Treatment and CareR01DA031059 · NIDA · BOSTON MEDICAL CENTER · PI LINAS, BENJAMIN P. · 2012 to 2015
$2.1MImproving urine drug test utility to mitigate prescription opioid riskK23DA042168 · NIDA · BOSTON MEDICAL CENTER · PI LAROCHELLE, MARC · 2017 to 2021
$956kNIAID NIH HHS P30 AI042853NIAID NIH HHS T32 AI052074NIDA NIH HHS K23 DA042168NIDA NIH HHS P30 DA040500NIDA NIH HHS R01 DA031059NIDA NIH HHS R01 DA046527NIDA NIH HHS R25 DA013582NIDA NIH HHS R25 DA037190
Abstract
objectivesTo estimate the annual prevalence of opioid use disorder (OUD) in Massachusetts from 2011 to 2015.
methodsWe performed a multisample stratified capture-recapture analysis to estimate OUD prevalence in Massachusetts. Individuals identified from 6 administrative databases for 2011 to 2012 and 7 databases for 2013 to 2015 were linked at the individual level and included in the analysis. Individuals were stratified by age group, sex, and county of residence.
resultsThe OUD prevalence in Massachusetts among people aged 11 years or older was 2.72% in 2011 and 2.87% in 2012. Between 2013 and 2015, the prevalence increased from 3.87% to 4.60%. The greatest increase in prevalence was observed among those in the youngest age group (11-25 years), a 76% increase from 2011 to 2012 and a 42% increase from 2013 to 2015.
conclusionsIn Massachusetts, the OUD prevalence was 4.6% among people 11 years or older in 2015. The number of individuals with OUD is likely increasing, particularly among young people.
Indexed as
AdolescentAdultAge DistributionChildDrug OverdoseFemaleHumansMaleMassachusettsMiddle AgedNarcoticsOpioid-Related DisordersSex DistributionYoung AdultNarcotics
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.